• PDF / 169,493 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 66 Downloads / 158 Views

DOWNLOAD

REPORT

---

1 S

Treatment failure and anaphylactic reaction: 3 case reports In a retrospective study of 40 patients treated from January 2015 to February 2019, 3 patients including one female [ages and not all sexes stated] were described, who exhibited treatment failure or developed anaphylactic reaction during treatment with amphotericin B liposomal or meglumine antimonate for American cutaneous leishmaniasis [routes, durations of treatments to reactions onsets and outcomes not stated]. The patients, who had American cutaneous leishmaniasis, started receiving treatment with either amphotericin B liposomal 4 mg/kg/day for 5 days (2 patients) or meglumine antimonate 75 mg/kg/day for 21 days (1 patient). The patients in the amphotericin B liposomal arm were premedicated with hydrocortisone, dexchlorpheniramine and paracetamol [acetaminophen]. However, two patients, in whom American cutaneous leishmaniasis was caused by Leishmania braziliensis, exhibited treatment failure with amphotericin B liposomal (1 patient) and meglumine antimonate (1 patient). One female patient, who was receiving amphotericin B liposomal, developed anaphylactic reaction. Owing to the reaction, the patient’s amphotericin B liposomal therapy was changed to meglumine antimonate. Senchyna A, et al. American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate. British 803500792 Journal of Dermatology 183: 389-391, No. 2, Aug 2020. Available from: URL: http://doi.org/10.1111/bjd.18964

0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Sep 2020 No. 1821